Medicines Optimisation and Metabolic Risk in Severe Mental Illness: From Monitoring to Measurable Harm Reduction
Medicines optimisation in severe mental illness (SMI) is not simply about adherence. It is about balancing therapeutic benefit with predictable metabolic and cardiovascular risks, and ensuring those risks are actively managed. Within the Physical health, dual diagnosis and parity of esteem resources and the wider Mental health service models and pathways collection, the operational challenge is clear: blood tests are missed, weight gain is normalised, side effects are under-reported, and escalation is inconsistent. This article sets out a practical operating model that moves from passive monitoring to measurable harm reduction.
Where metabolic harm emerges in practice
Metabolic risk accumulates gradually. Weight gain, rising blood pressure, impaired glucose tolerance and lipid changes often develop over months. In community mental health settings, these changes are easily overshadowed by mental state concerns. Harm emerges not from one missed test, but from drift: overdue monitoring, results filed without action, and no structured follow-up.
An effective model defines ownership, cadence, and response thresholds.
The medicines optimisation framework
1) Defined monitoring schedules embedded into care pathways
Each person prescribed medicines associated with metabolic risk should have a clearly recorded monitoring schedule aligned to clinical guidance and local agreements with prescribers. The service maintains visibility of what is due and when, even where primary care completes the test. The emphasis is on ensuring completion and documented review, not duplicating clinical roles.
2) Side-effect surveillance integrated into routine contact
Staff embed short, structured prompts into regular contact: changes in appetite, rapid weight gain, increased thirst, urinary changes, sedation, reduced activity tolerance. These prompts are documented consistently, creating a visible trend over time rather than isolated notes.
3) Clear escalation triggers and shared decision-making
Escalation thresholds must be explicit. For example: significant weight gain over a defined period, abnormal blood results, new onset hypertension, or marked sedation affecting safety. Escalation may include prescriber review, GP contact, or adjustment of lifestyle support. Decisions are documented with the person’s informed involvement.
4) Converting findings into practical routines
Metabolic monitoring only reduces harm when findings change daily practice. Action plans should include structured meal planning, realistic activity routines, smoking reduction support if desired, and agreed follow-up dates. Staff review progress at defined intervals and record measurable change.
Operational examples (minimum three)
Operational example 1: Early intervention for rapid weight gain
Context: A person newly prescribed antipsychotic medication gains significant weight within three months. Historically, this would be noted but not acted on until annual review.
Support approach: The service applies a results-to-action model with same-month escalation and co-produced lifestyle planning.
Day-to-day delivery detail: Staff identify weight gain through routine monitoring and schedule a prescriber discussion within one week. They co-produce a structured weekly plan: two supported shopping sessions per month, a simple meal structure, and a 15-minute daily walking routine. A repeat weight check is booked in four weeks. Staff document progress weekly and escalate if weight continues to rise.
How effectiveness is evidenced: Evidence includes stabilisation or reduction in weight trajectory over three months, documented prescriber input, and clear records of lifestyle plan implementation.
Operational example 2: Closing the loop on abnormal blood results
Context: Blood tests show rising HbA1c and lipid levels. Results are uploaded to records but no follow-up conversation occurs.
Support approach: The service introduces a “results reviewed and actioned” standard requiring documented follow-up within defined timescales.
Day-to-day delivery detail: Within five working days of receiving results, a staff member meets the person to explain findings in plain language and confirm next steps (GP review, dietary changes, medication discussion). A follow-up appointment is booked before the case is marked complete. Progress is reviewed at one and three months.
How effectiveness is evidenced: Audit shows abnormal results are reviewed and actioned within timescale. Trend data demonstrates improved monitoring reliability and reduced delay between result and intervention.
Operational example 3: Managing sedation and falls risk
Context: A person reports daytime drowsiness and two minor falls. Medication side effects are suspected but not formally reviewed.
Support approach: The service treats sedation as a safety risk requiring structured assessment and escalation.
Day-to-day delivery detail: Staff complete a falls and sedation prompt during contact, document incidents, and escalate to the prescriber within 48 hours. A temporary increase in support contact ensures safety while review is pending. Environmental adjustments are discussed, and hydration and sleep routine are reviewed. Follow-up is documented after medication review.
How effectiveness is evidenced: Evidence includes documented prescriber response, reduction in falls incidents, and improved daytime functioning recorded in support notes.
Explicit expectations (mandatory)
Commissioner expectation
Commissioners typically expect evidence that medicines-related metabolic risks are monitored reliably, escalated promptly, and linked to measurable harm reduction. They will look for audit data demonstrating completion of monitoring schedules, timely action on abnormal findings, and reduced avoidable urgent care related to unmanaged physical health risk.
Regulator / Inspector expectation (e.g., CQC)
Inspectors typically expect safe medicines management, recognition of side effects, timely escalation, and documentation showing informed involvement of the person in decisions. They will also examine whether services learn from incidents such as falls or deterioration potentially linked to medication.
Governance and assurance mechanisms
- Medicines monitoring register with due dates and action status.
- Quarterly metabolic risk audit sampling closed-loop practice.
- Incident review linkage examining whether metabolic or sedation risk contributed to harm.
- Supervision prompts focused on one medicines-risk case monthly.
Medicines optimisation becomes credible when monitoring is reliable, escalation is timely, and outcomes are measurable rather than assumed.